DEA No. 9720
DEA No. 9720 Brand names, DEA No. 9720 Analogs
DEA No. 9720 Brand Names Mixture
- No information avaliable
DEA No. 9720 Chemical_Formula
C21H29NO2
DEA No. 9720 RX_link
http://www.rxlist.com/cgi/generic2/butor.htm
DEA No. 9720 fda sheet
DEA No. 9720 msds (material safety sheet)
DEA No. 9720 Synthesis Reference
No information avaliable
DEA No. 9720 Molecular Weight
327.461 g/mol
DEA No. 9720 Melting Point
No information avaliable
DEA No. 9720 H2O Solubility
Moderate
DEA No. 9720 State
Solid
DEA No. 9720 LogP
4.176
DEA No. 9720 Dosage Forms
Drops; Drug premix; Gel; Globules; Liquid; Powder for solution; Solution; Spray; Tablet
DEA No. 9720 Indication
For the management of pain when the use of an opioid analgesic is appropriate. Also indicated as a preoperative or preanesthetic medication, as a supplement to balanced anesthesia, and for the relief of pain during labor.
DEA No. 9720 Pharmacology
Butorphanol is a synthetic opioid agonist-antagonist analgesic with a pharmacological and therapeutic profile that has been well established since its launch as a parenteral formulation in 1978. The introduction of a transnasal formulation of butorphanol represents a new and noninvasive presentation of an analgesic for moderate to severe pain. This route of administration bypasses the gastrointestinal tract, and this is an advantage for a drug such as butorphanol that undergoes significant first-pass metabolism after oral administration. The onset of action and systemic bioavailability of butorphanol following transnasal delivery are similar to those after parenteral administration. Butorphanol blocks pain impulses at specific sites in the brain and spinal cord.
DEA No. 9720 Absorption
Rapidly absorbed after intramuscular injection and peak plasma levels are reached in 20-40 minutes. The absolute bioavailability is 60-70% and is unchanged in patients with allergic rhinitis. In patients using a nasal vasoconstrictor (oxymetazoline) the fraction of the dose absorbed was unchanged, but the rate of absorption was slowed. Oral bioavailability is only 5-17% because of extensive first-pass metabolism.
DEA No. 9720 side effects and Toxicity
The clinical manifestations of butorphanol overdose are those of opioid drugs in general. The most serious symptoms are hypoventilation, cardiovascular insufficiency, coma, and death.
DEA No. 9720 Patient Information
DEA No. 9720 Organisms Affected
Humans and other mammals
